Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.00 Average Price Target from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $21.00.

Separately, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a "buy" rating and a $20.00 target price for the company.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $1,337,000. Geode Capital Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $4,774,000. Barclays PLC acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $304,000. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $42,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth approximately $166,000.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV traded down $0.81 during mid-day trading on Friday, hitting $5.06. 112,620 shares of the company's stock traded hands, compared to its average volume of 109,203. The firm's 50 day simple moving average is $5.50 and its 200 day simple moving average is $9.68. Artiva Biotherapeutics has a 1 year low of $3.37 and a 1 year high of $17.31.

Remove Ads

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.